Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Bellini, A
  • Pötschger U
  • Bernard, V
  • Lapouble, E
  • Baulande, S
  • Ambros, PF
  • Auger, N
  • Beiske, K
  • Bernkopf, M
  • Betts, DR
  • Bhalshankar, J
  • Bown, N
  • de Preter, K
  • Clément, N
  • Combaret, V
  • George, SL
  • Jiménez, I
  • Jeison, M
  • Marques, B
  • Martinsson, T
  • Mazzocco, K
  • Morini, M
  • Mühlethaler-Mottet, A
  • Noguera, R
  • Pierron, G
  • Rossing, M
  • Taschner-Mandl, S
  • Van Roy, N
  • Vicha, A
  • Chesler, L
  • Balwierz, W
  • Elliott, M
  • Kogner, P
  • Laureys, G
  • Luksch, R
  • Malis, J
  • Popovic-Beck, M
  • Ash, S
  • Delattre, O
  • Valteau-Couanet, D
  • Tweddle, DA
  • Ladenstein, R
  • Schleiermacher, G

Grupos

Abstract

In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact.

Datos de la publicación

ISSN/ISSNe:
0732-183X, 1527-7755

JOURNAL OF CLINICAL ONCOLOGY  LIPPINCOTT WILLIAMS & WILKINS

Tipo:
Article
Páginas:
3377-3390
PubMed:
34115544
Factor de Impacto:
9,378 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 65

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • SEGMENTAL CHROMOSOMAL ALTERATIONS; ACTIVATING MUTATIONS; PEDIATRIC-PATIENTS; CRIZOTINIB; REVEALS; RELAPSE; KINASE; REARRANGEMENTS; HETEROGENEITY; CHEMOTHERAPY

Campos de Estudio

Cita

Compartir